

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
SIGNIFICANT DECREASE IN LOSS OF THE COMPANY'S RESULTS

This announcement is made by AIM VACCINE Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

Based on a preliminary assessment by the board of directors of the Company (the “**Board**”) of the Group’s unaudited consolidated management accounts for the year ended December 31, 2024 (the “**Reporting Period**”) and the information currently available to the Board, the Group is expected to record an unaudited revenue ranging from RMB1.25 billion to RMB1.3 billion for the Reporting Period, representing an increase ranging from RMB60 million to RMB110 million or 5% to 9% as compared to the revenue of RMB1.19 billion for the previous year; and the Group is expected to record an unaudited net loss ranging from RMB250 million to RMB290 million, representing a significant decrease in loss ranging from RMB1.66 billion to RMB1.7 billion or 85% to 87% as compared to the net loss of RMB1.95 billion in the previous year. The Board is of the preliminary view that, the increase in revenue was mainly due to the increased revenue from HBV vaccination of the Company, and the decrease in comprehensive net loss was mainly due to the decrease in the amount of significant asset impairment losses and the increase in revenue during the year.

The information contained in this announcement is prepared only based on the information currently available to the Board and a preliminary assessment of the consolidated management accounts of the Group for the Reporting Period which have not been confirmed, reviewed or audited by the independent auditor of the Company. The audited results of the Group for the Reporting Period may differ from what is disclosed in this announcement. Shareholders and potential investors are advised to refer to the results announcement of the Group for the Year 2024 which is expected to be published in late March 2025.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, March 17, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.